Page last updated: 2024-09-04

satavaptan and Liver Cirrhosis

satavaptan has been researched along with Liver Cirrhosis in 20 studies

Research

Studies (20)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's5 (25.00)29.6817
2010's14 (70.00)24.3611
2020's1 (5.00)2.80

Authors

AuthorsStudies
Aagaard, NK; Gantzel, RH; Grønbaek, H; Jepsen, P; Vilstrup, H; Watson, H1
Jepsen, P; Vilstrup, H; Watson, H; Wong, F1
Andersen, PK; Bossen, L; Dam, G; Jepsen, P; Vilstrup, H; Watson, H1
Ginès, P; Guevara, M; Vilstrup, H; Watson, H1
Córdoba, J; Ginès, P; Jepsen, P; Vilstrup, H; Watson, H; Wong, F1
Kwo, PY1
Andersen, PK; Jepsen, P; Vilstrup, H; Watson, H1
Bossen, L; Jepsen, P; Krag, A; Vilstrup, H; Watson, H1
del Arbol, LR; Ginès, P; Milutinovic, S; Olteanu, D; Watson, H; Wong, F1
Ginès, P; Guevara, M1
Bruha, R; Dudley, F; Ginès, P; Terg, R; Watson, H; Wong, F; Zarski, JP1
Angeli, P; Bernardi, M; Gines, P; Gow, P; Horsmans, Y; Minini, P; Watson, H; Wong, F1
Accordino, S; Cazzaniga, M; Salerno, F1
Villabona, C1
Er, F; Fuhr, U; Gassanov, N; Nia, AM; Semmo, M; Semmo, N1
Badalamenti, S; Bernardi, M; Gerbes, A; Ginès, P; Vilstrup, H; Watson, H; Wong, F1
Dahl, E; Gluud, LL; Kimer, N; Krag, A1
Ferguson, JW; Hayes, PC; Newby, DE; Therapondos, G1
Ali, F; Ghali, JK; Guglin, M; Vaitkevicius, P1
Jiménez, W1

Reviews

8 review(s) available for satavaptan and Liver Cirrhosis

ArticleYear
Satavaptan treatment for ascites in patients with cirrhosis: a meta-analysis of effect on hepatic encephalopathy development.
    Metabolic brain disease, 2013, Volume: 28, Issue:2

    Topics: Antidiuretic Hormone Receptor Antagonists; Ascites; Hepatic Encephalopathy; Humans; Kaplan-Meier Estimate; Liver Cirrhosis; Morpholines; Multicenter Studies as Topic; Randomized Controlled Trials as Topic; Research Design; Spiro Compounds; Survival Analysis

2013
Hyponatremia in cirrhosis: pathogenesis, clinical significance, and management.
    Hepatology (Baltimore, Md.), 2008, Volume: 48, Issue:3

    Topics: Antidiuretic Hormone Receptor Antagonists; Arginine Vasopressin; Humans; Hyponatremia; Liver Cirrhosis; Morpholines; Sodium; Spiro Compounds

2008
[Vasopressin receptor antagonists: the vaptans].
    Endocrinologia y nutricion : organo de la Sociedad Espanola de Endocrinologia y Nutricion, 2010, Volume: 57 Suppl 2

    Topics: Adult; Antidiuretic Hormone Receptor Antagonists; Aquaporin 2; Benzamides; Benzazepines; Calcium Signaling; Clinical Trials as Topic; Cyclic AMP; Double-Blind Method; Drug Therapy, Combination; Heart Failure; Humans; Hyponatremia; Inappropriate ADH Syndrome; Kidney Tubules, Collecting; Liver Cirrhosis; Morpholines; Multicenter Studies as Topic; Neoplasms; Pituitary Gland, Anterior; Pyrroles; Randomized Controlled Trials as Topic; Receptors, Vasopressin; Second Messenger Systems; Spiro Compounds; Tolvaptan; Vasopressins

2010
Arginine vasopressin (AVP) and treatment with arginine vasopressin receptor antagonists (vaptans) in congestive heart failure, liver cirrhosis and syndrome of inappropriate antidiuretic hormone secretion (SIADH).
    European journal of clinical pharmacology, 2011, Volume: 67, Issue:4

    Topics: Antidiuretic Hormone Receptor Antagonists; Benzamides; Benzazepines; Diuretics; Heart Failure; Humans; Inappropriate ADH Syndrome; Liver Cirrhosis; Models, Biological; Morpholines; Pyrroles; Spiro Compounds; Tolvaptan; Water-Electrolyte Balance

2011
Meta-analysis: the safety and efficacy of vaptans (tolvaptan, satavaptan and lixivaptan) in cirrhosis with ascites or hyponatraemia.
    Alimentary pharmacology & therapeutics, 2012, Volume: 36, Issue:7

    Topics: Antidiuretic Hormone Receptor Antagonists; Ascites; Benzamides; Benzazepines; Humans; Hyponatremia; Liver Cirrhosis; Morpholines; Pyrroles; Randomized Controlled Trials as Topic; Receptors, Vasopressin; Sodium; Spiro Compounds; Tolvaptan; Treatment Outcome

2012
Therapeutic role of vasopressin receptor antagonism in patients with liver cirrhosis.
    Clinical science (London, England : 1979), 2003, Volume: 105, Issue:1

    Topics: Animals; Antidiuretic Hormone Receptor Antagonists; Azepines; Benzamides; Benzazepines; Controlled Clinical Trials as Topic; Diuretics; Heart Failure; Homeostasis; Humans; Inappropriate ADH Syndrome; Liver Cirrhosis; Models, Animal; Morpholines; Piperidines; Pyrroles; Quinolones; Rats; Spiro Compounds; Vasopressins

2003
Therapeutic potential of vasopressin receptor antagonists.
    Drugs, 2007, Volume: 67, Issue:6

    Topics: Animals; Antidiuretic Hormone Receptor Antagonists; Arginine Vasopressin; Azepines; Benzamides; Benzazepines; Heart Failure; Humans; Hyponatremia; Inappropriate ADH Syndrome; Liver Cirrhosis; Morpholines; Pyrroles; Receptors, Vasopressin; Spiro Compounds; Tolvaptan

2007
[Aquaretic agents].
    Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia, 2002, Volume: 22 Suppl 5

    Topics: Animals; Antidiuretic Hormone Receptor Antagonists; Aquaporin 2; Aquaporin 6; Aquaporins; Ascites; Benzeneacetamides; Body Water; Demeclocycline; Diuresis; Diuretics; Humans; Kidney Tubules, Collecting; Liver Cirrhosis; Liver Cirrhosis, Experimental; Morpholines; Pyrrolidines; Rats; Receptors, Opioid, kappa; Receptors, Vasopressin; Spiro Compounds; Vasopressins

2002

Trials

8 trial(s) available for satavaptan and Liver Cirrhosis

ArticleYear
Development and validation of the Cirrhotic Ascites Severity model-A patient-reported outcome-based model to predict 1-year mortality.
    Hepatology communications, 2022, Volume: 6, Issue:11

    Topics: Ascites; Diuretics; End Stage Liver Disease; Humans; Liver Cirrhosis; Patient Reported Outcome Measures; Severity of Illness Index; Sodium

2022
Un-precipitated acute kidney injury is uncommon among stable patients with cirrhosis and ascites.
    Liver international : official journal of the International Association for the Study of the Liver, 2018, Volume: 38, Issue:10

    Topics: Acute Kidney Injury; Aged; Ascites; Creatinine; Diuretics; Female; Humans; Internationality; Liver Cirrhosis; Male; Middle Aged; Morpholines; Paracentesis; Prognosis; Proportional Hazards Models; Severity of Illness Index; Spiro Compounds

2018
Diabetes as a risk factor for hepatic encephalopathy in cirrhosis patients.
    Journal of hepatology, 2015, Volume: 63, Issue:5

    Topics: Aged; Antidiuretic Hormone Receptor Antagonists; Diabetes Mellitus; Dose-Response Relationship, Drug; Female; Follow-Up Studies; France; Hepatic Encephalopathy; Humans; Incidence; Liver Cirrhosis; Male; Middle Aged; Morpholines; Prognosis; Retrospective Studies; Risk Assessment; Risk Factors; Spiro Compounds; Survival Rate; Time Factors

2015
Nonselective β-blockers do not affect mortality in cirrhosis patients with ascites: Post Hoc analysis of three randomized controlled trials with 1198 patients.
    Hepatology (Baltimore, Md.), 2016, Volume: 63, Issue:6

    Topics: Adrenergic beta-Antagonists; Antidiuretic Hormone Receptor Antagonists; Ascites; Female; Gastrointestinal Hemorrhage; Humans; Liver Cirrhosis; Male; Middle Aged; Morpholines; Spiro Compounds

2016
Effects of satavaptan, a selective vasopressin V(2) receptor antagonist, on ascites and serum sodium in cirrhosis with hyponatremia: a randomized trial.
    Hepatology (Baltimore, Md.), 2008, Volume: 48, Issue:1

    Topics: Aged; Antidiuretic Hormone Receptor Antagonists; Ascites; Blood Circulation; Diuretics; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Hyponatremia; Kidney; Liver Cirrhosis; Male; Middle Aged; Morpholines; Renin-Angiotensin System; Sodium; Spiro Compounds; Treatment Outcome

2008
Clinical trial: short-term effects of combination of satavaptan, a selective vasopressin V2 receptor antagonist, and diuretics on ascites in patients with cirrhosis without hyponatraemia--a randomized, double-blind, placebo-controlled study.
    Alimentary pharmacology & therapeutics, 2010, Volume: 31, Issue:8

    Topics: Aged; Antidiuretic Hormone Receptor Antagonists; Ascites; Body Weight; Diuretics; Double-Blind Method; Drug Combinations; Female; Furosemide; Humans; Liver Cirrhosis; Male; Middle Aged; Morpholines; Prospective Studies; Spiro Compounds; Spironolactone; Treatment Outcome

2010
Effects of a selective vasopressin V2 receptor antagonist, satavaptan, on ascites recurrence after paracentesis in patients with cirrhosis.
    Journal of hepatology, 2010, Volume: 53, Issue:2

    Topics: Aged; Antidiuretic Hormone Receptor Antagonists; Ascites; Combined Modality Therapy; Creatinine; Diuretics; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Hyponatremia; Liver Cirrhosis; Male; Middle Aged; Morpholines; Paracentesis; Secondary Prevention; Spiro Compounds; Spironolactone; Thirst; Treatment Outcome

2010
Satavaptan for the management of ascites in cirrhosis: efficacy and safety across the spectrum of ascites severity.
    Gut, 2012, Volume: 61, Issue:1

    Topics: Aged; Antidiuretic Hormone Receptor Antagonists; Ascites; Diuretics; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Kaplan-Meier Estimate; Liver Cirrhosis; Male; Middle Aged; Morpholines; Proportional Hazards Models; Secondary Prevention; Spiro Compounds; Treatment Outcome

2012

Other Studies

4 other study(ies) available for satavaptan and Liver Cirrhosis

ArticleYear
Effect of proton pump inhibitors on the risk and prognosis of infections in patients with cirrhosis and ascites.
    Liver international : official journal of the International Association for the Study of the Liver, 2019, Volume: 39, Issue:3

    Topics: Antidiuretic Hormone Receptor Antagonists; Ascites; Bacterial Infections; Female; Humans; Incidence; Liver Cirrhosis; Male; Middle Aged; Morpholines; Multicenter Studies as Topic; Peritonitis; Proton Pump Inhibitors; Randomized Controlled Trials as Topic; Risk Assessment; Risk Factors; Spiro Compounds; Time Factors; Treatment Outcome

2019
Improvement of hyponatremia in cirrhosis is associated with improved complex information processing.
    Journal of gastroenterology and hepatology, 2019, Volume: 34, Issue:11

    Topics: Cognition; Humans; Hyponatremia; Liver Cirrhosis; Male; Middle Aged; Morpholines; Sodium; Spiro Compounds; Treatment Outcome

2019
Management of hyponatremia in clinical hepatology practice.
    Current gastroenterology reports, 2014, Volume: 16, Issue:5

    Topics: Antidiuretic Hormone Receptor Antagonists; Benzazepines; Drinking Behavior; Fluid Therapy; Humans; Hyponatremia; Liver Cirrhosis; Morpholines; Spiro Compounds; Tolvaptan

2014
May vaptans contribute to the treatment of refractory ascites?
    Journal of hepatology, 2010, Volume: 53, Issue:2

    Topics: Antidiuretic Hormone Receptor Antagonists; Ascites; Combined Modality Therapy; Diuretics; Dose-Response Relationship, Drug; Humans; Hyponatremia; Liver Cirrhosis; Morpholines; Paracentesis; Spiro Compounds; Spironolactone; Treatment Outcome

2010